Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Jiangsu Lianhuan Pharmaceutical Co's share price is ¥16.64.
Jiangsu Lianhuan Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥9.70. Hence, Jiangsu Lianhuan Pharmaceutical Co's PS Ratio for today is 1.71.
During the past 13 years, Jiangsu Lianhuan Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 28.80% per year. The lowest was -2.80% per year. And the median was 15.65% per year.
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Jiangsu Lianhuan Pharmaceutical Co PS Ratio Related Terms
Jiangsu Lianhuan Pharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Lianhuan Pharmaceutical Co PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's PS Ratio falls into.
Jiangsu Lianhuan Pharmaceutical Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Jiangsu Lianhuan Pharmaceutical Co's Share Price of today is ¥16.64. Jiangsu Lianhuan Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥9.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a PS Ratio of 1.71 as of Aug. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. This is near median its historical median of 1.83. Over the past decade, Jiangsu Lianhuan Pharmaceutical Co's PS Ratio has ranged from 0.96 to 6.15. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #377 out of 949 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Jiangsu Lianhuan Pharmaceutical Co's PS Ratio too high?
Jiangsu Lianhuan Pharmaceutical Co's current PS Ratio of 1.71 is near median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 6.15. The Drug Manufacturers industry median PS Ratio is 2.36. Jiangsu Lianhuan Pharmaceutical Co's value of 1.71 is 27.5% below this industry median. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #377 out of 949 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #377 out of 949 companies for PS Ratio. This puts Jiangsu Lianhuan Pharmaceutical Co in the upper half of its industry. The industry median PS Ratio is 2.36. Jiangsu Lianhuan Pharmaceutical Co's value of 1.71 is 27.5% below this benchmark. Historically, Jiangsu Lianhuan Pharmaceutical Co's own PS Ratio has ranged from 0.96 to 6.15 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 2.36, Jiangsu Lianhuan Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.36, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Lianhuan Pharmaceutical Co's current PS Ratio of 1.71 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Lianhuan Pharmaceutical Co's current PS Ratio is 1.71, which is near median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.83, compared to a current price of ¥16.64 — trading 20.3% above its estimated fair value. The current PS Ratio is 1.71, which is near median its 10-year median of 1.83 and 27.5% below the Drug Manufacturers industry median of 2.36. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 63/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current PS Ratio is 1.71 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥16.64 is trading 20.3% above its estimated GF Value™ of ¥13.83.
GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600513:
PS Ratio: 1.71 (near median its 10-year median of 1.83)
GF Value™: ¥13.83 vs. price of ¥16.64 (20.3% above fair value)
Industry Position: 27.5% below the Drug Manufacturers median (#377 of 949)
No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
63GF Score
Get the complete analysis for SHSE:600513
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600513 has been successfully added to your 
